| 摘要: |
| ［摘要］目的 观察恩替卡韦联合还原型谷胱甘肽治疗对慢性乙肝患者血清肝纤维化指标的影响．方法 随机选取2012年2月至2014年3月间在仙桃市第一人民医院接受治疗的慢性乙肝患者84例，将所有入选患者随机分为2组，治疗组（还原型谷胱甘肽联合恩替卡韦治疗，n＝43），对照组（单用恩替卡韦治疗，n＝41），比较2组患者治疗后、治疗组治疗前后血清肝纤维化指标的变化．结果（1）治疗后治疗组患者血清肝纤维化指标明显低于对照组（P＜0.05），差异有统计学意义；（2）治疗后治疗组肝维化指标明显低于治疗前（P＜0.05），差异有统计学意义．结论 还原型谷胱甘肽联合恩替卡韦治疗能有效地降低血清肝纤维化指标的水平，延缓肝纤维化形成进程． |
| 关键词: ［关键词］慢性乙肝 还原型谷胱甘肽 恩替卡韦 肝纤维化指标 |
| DOI： |
| 分类号: |
| 基金项目:［基金项目］国家自然科学基金资助项目（81172178） |
|
| The Influence of GSH Combined ETV on Liver Fibrosis Indexes of Patients with CHB |
|
ZHOU Ying1,2
|
|
1.（1）The First People’s Hospital of Xiantao Hubei，Xiantao Hubei 433000;2）Wuhan Institute of Technology，Wuhan Hubei 430032，China）
|
| Abstract: |
| ［Abstract］Objective To observe the influence of glutathion（GSH）combined entecavir（ETV） on the serum levels of liver fibrosis indexes of patients with chronic hepatitis B（CHB）. Methods We randomly selected 84 cases of patients treated with CHB from February 2012 to March 2014 in our hospital，all the selected patients were randomly divided into 2 groups: the treatment group（GSH combined ETV treatment，n＝43） and the control group （use ETV treatment，n＝41）. The serum liver fibrosis indexes were compared between two groups after treatment. The serum liver fibrosis indexes were compared between pre -and post- treatment in the treatment group．Results（1）After treatment， serum liver fibrosis indexes of the treatment group were significantly lower than those in control group （P < 0.05）， the difference was statistically significant.（2）In the control group， the serum liver fibrosis indexes of post-treatment were significantly lower than those pre-treatment's（P < 0.05）， the difference was statistically significant. Conclusion The combination therapy of GSH and ETV can effectively reduce the serum levels of liver fibrosis indexes and delay the formation process of liver fibrosis. |
| Key words: ［Key words］Chronic hepatitis B GSH ETV Liver fibrosis indexes |